Literature DB >> 26297794

Serum amyloid A1α induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils.

Mieke De Buck1, Nele Berghmans1, Noëmie Pörtner1, Lotte Vanbrabant1, Maaike Cockx1, Sofie Struyf1, Ghislain Opdenakker1, Paul Proost1, Jo Van Damme2, Mieke Gouwy1.   

Abstract

Cell migration depends on the ability of leukocytes to sense an external gradient of chemotactic proteins produced during inflammation. These proteins include chemokines, complement factors, and some acute phase proteins, such as serum amyloid A. Serum amyloid A chemoattracts neutrophils, monocytes, and T lymphocytes via its G protein-coupled receptor formyl peptide receptor 2. We demonstrate that serum amyloid A1α more potently chemoattracts neutrophils in vivo than in vitro. In contrast to CD14(+) monocytes, no rapid (within 2 h) induction of interleukin-8/CXC chemokine ligand 8 or macrophage-inflammatory protein-1α/CC chemokine ligand 3 was observed in purified human neutrophils after stimulation of the cells with serum amyloid A1α or lipopolysaccharide. Moreover, interleukin-8/CXC chemokine ligand 8 induction in monocytes by serum amyloid A1α was mediated by toll-like receptor 2 and was inhibited by association of serum amyloid A1α with high density lipoprotein. This indicates that the potent chemotactic response of neutrophils toward intraperitoneally injected serum amyloid A1α is indirectly enhanced by rapid induction of chemokines in peritoneal cells, synergizing in a paracrine manner with serum amyloid A1α. We observed direct synergy between IL-8/CXC chemokine ligand 8 and serum amyloid A1α, but not lipopolysaccharide, in chemotaxis and shape change assays with neutrophils. Furthermore, the selective CXC chemokine receptor 2 and formyl peptide receptor 2 antagonists, SB225002 and WRW4, respectively, blocked the synergy between IL-8/CXC chemokine ligand 8 and serum amyloid A1α in neutrophil chemotaxis in vitro, indicating that for synergy their corresponding G protein-coupled receptors are required. Additionally, SB225002 significantly inhibited serum amyloid A1α-mediated peritoneal neutrophil influx. Taken together, endogenous (e.g., IL-1β) and exogenous (e.g., lipopolysaccharide) inflammatory mediators induce primary chemoattractants such as serum amyloid A that synergize in an autocrine (monocyte) or a paracrine (neutrophil) fashion with secondary chemokines induced in stromal cells. © Society for Leukocyte Biology.

Entities:  

Keywords:  G protein-coupled receptor; chemoattractants; chemotaxis

Mesh:

Substances:

Year:  2015        PMID: 26297794     DOI: 10.1189/jlb.3A0315-085R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

1.  Serum amyloid A: an ozone-induced circulating factor with potentially important functions in the lung-brain axis.

Authors:  Michelle A Erickson; Joseph Jude; Hengjiang Zhao; Elizabeth M Rhea; Therese S Salameh; William Jester; Shelley Pu; Jenna Harrowitz; Ngan Nguyen; William A Banks; Reynold A Panettieri; Kelly L Jordan-Sciutto
Journal:  FASEB J       Date:  2017-05-22       Impact factor: 5.191

Review 2.  The cytokine-serum amyloid A-chemokine network.

Authors:  Mieke De Buck; Mieke Gouwy; Ji Ming Wang; Jacques Van Snick; Paul Proost; Sofie Struyf; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

3.  Serum Amyloid A Contributes to Chronic Apical Periodontitis via TLR2 and TLR4.

Authors:  K Hirai; H Furusho; N Kawashima; S Xu; M C de Beer; R Battaglino; T Van Dyke; P Stashenko; H Sasaki
Journal:  J Dent Res       Date:  2018-09-06       Impact factor: 6.116

4.  Phenotypical and Functional Characterization of Neutrophils in Two Pyrin-Associated Auto-inflammatory Diseases.

Authors:  Bert Malengier-Devlies; Mieke Metzemaekers; Mieke Gouwy; Erika Van Nieuwenhove; Albrecht Betrains; Maaike Cockx; Lotte Vanbrabant; Noëmie Pörtner; Jurgen Vercauteren; Lien De Somer; Sofie Struyf; Steven Vanderschueren; Ellen De Langhe; Paul Proost; Patrick Matthys; Carine Wouters
Journal:  J Clin Immunol       Date:  2021-03-05       Impact factor: 8.317

Review 5.  The turning away of serum amyloid A biological activities and receptor usage.

Authors:  Sara Abouelasrar Salama; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Immunology       Date:  2021-01-04       Impact factor: 7.215

Review 6.  Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults.

Authors:  Mieke De Buck; Mieke Gouwy; Ji Ming Wang; Jacques Van Snick; Ghislain Opdenakker; Sofie Struyf; Jo Van Damme
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

7.  Matrix Metalloproteinase-9-Generated COOH-, but Not NH2-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity.

Authors:  Mieke Gouwy; Mieke De Buck; Sara Abouelasrar Salama; Jennifer Vandooren; Sofie Knoops; Noëmie Pörtner; Lotte Vanbrabant; Nele Berghmans; Ghislain Opdenakker; Paul Proost; Jo Van Damme; Sofie Struyf
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

8.  Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1.

Authors:  Sara Abouelasrar Salama; Mirre De Bondt; Mieke De Buck; Nele Berghmans; Paul Proost; Vivian Louise Soares Oliveira; Flavio A Amaral; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Front Immunol       Date:  2020-05-14       Impact factor: 7.561

9.  Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells.

Authors:  Tadeja Kuret; Katja Lakota; Polonca Mali; Saša Čučnik; Sonja Praprotnik; Matija Tomšič; Snezna Sodin-Semrl
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

10.  Neutrophils from Patients with Primary Ciliary Dyskinesia Display Reduced Chemotaxis to CXCR2 Ligands.

Authors:  Maaike Cockx; Mieke Gouwy; Véronique Godding; Kris De Boeck; Jo Van Damme; Mieke Boon; Sofie Struyf
Journal:  Front Immunol       Date:  2017-09-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.